PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis

Clin Epigenetics. 2021 Aug 9;13(1):156. doi: 10.1186/s13148-021-01147-w.

Abstract

Skeletal muscle formation represents a complex of highly organized and specialized systems that are still not fully understood. Epigenetic systems underline embryonic development, maintenance of stemness, and progression of differentiation. Polycomb group proteins play the role of gene silencing of stemness markers that regulate muscle differentiation. Enhancer of Zeste EZH2 is the catalytic subunit of the complex that is able to trimethylate lysine 27 of histone H3 and induce silencing of the involved genes. In embryonal Rhabdomyosarcoma and several other tumors, EZH2 is often deregulated and, in some cases, is associated with tumor malignancy. This review explores the molecular processes underlying the failure of muscle differentiation with a focus on the PRC2 complex. These considerations could open new studies aimed at the development of new cutting-edge therapeutic strategies in the onset of Rhabdomyosarcoma.

Keywords: Cancer; EZH2; Epigenetics; Histone modification; Methyltransferase; Rhabdomyosarcoma.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinogenesis / genetics*
  • Cell Differentiation
  • Epigenesis, Genetic
  • Humans
  • Muscle Development / genetics*
  • Muscle, Skeletal / physiopathology*
  • Neoplasm Proteins / genetics*
  • Polycomb Repressive Complex 2 / genetics*
  • Rhabdomyosarcoma / genetics*
  • Rhabdomyosarcoma / physiopathology*

Substances

  • Neoplasm Proteins
  • Polycomb Repressive Complex 2